Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Board recommends continuation of Biomira's phase IIb trial of BLP25 in NSCLC

Jan. 31, 2002

Rituximab + CHOP as a new drug combination for aggressive NHL

Jan. 29, 2002

Phase IIb results reported for OvaRex in metastatic ovarian cancer

Jan. 29, 2002

Patient enrollment completed in trial of G17DT in gastric cancer

Jan. 25, 2002

Progen enrolls first patient in phase II trial of PI-88 in multiple myeloma

Jan. 24, 2002

Survival data announced from phase II trial of GD-0039 in metastatic renal cancer

Jan. 23, 2002

Arius postpones murine ARH460-23 antibody development

Jan. 22, 2002

Initiation of phase III trial of Ceplene/IL-2 in metastatic melanoma with liver metastases

Jan. 21, 2002

Interferon Sciences explores cancer indications for Alferon N Injection

Jan. 16, 2002

High-dose HspE7 effective and well tolerated in high-grade anal dysplasia

Jan. 14, 2002

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 26, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 23, 2026
Brain-computer interfaces are here but long road ahead
BioWorld
The field of BCI is continually evolving; as such, companies are increasingly highlighting the potential of their technologies to transform care. For advanced...
2026 marks critical turning point for BCI technology
BioWorld
Decades of research are helping unravel the “black box” of the brain. The second article in BioWorld’s series on the Brain-Computer Interface (BCI) field looks at...
Case report links APOLD1 variant to vascular-type bleeding disorder
BioWorld Science
Vascular-type bleeding disorder (BDVAS) is a rare, autosomal dominant disorder mainly caused by impaired vascular integrity.